|

Assessing DCog Short for Neurotoxicity in CAR-T

RECRUITINGN/ASponsored by Beth Israel Deaconess Medical Center
Actively Recruiting
PhaseN/A
SponsorBeth Israel Deaconess Medical Center
Started2026-04-13
Est. completion2027-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
* Visual acuity of 20/100 or better.

Exclusion Criteria:

* patients \< 18 years old
* pregnant women
* prisoners
* adults unable to consent,
* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad

Conditions5

CancerHematologic MalignancyImmune Effector Cell Associated Neurotoxicity SyndromeNeurotoxicityNeurotoxicity Syndromes

Locations1 site

Beth Israel Deaconess Medical Center
Jon Arnason, MD617-667-9920jarnason@bidmc.harvard.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.